About Us Resources Catalysts Start Free Trial →

Loading…

Day Trader Sniper provides algorithmic alerts and analysis, not trade advice.
Not financial advice. Trade at your own risk.

Quick Links

Download The App Resources Market Feed Stocks

Catalysts About Us Support Privacy policy Terms of use

©2026 Day Trader Sniper - all rights reserved

Home›Catalysts›Regulatory and Clinical

Catalyst Category

Regulatory and Clinical

Live feed of every catalyst classified under Regulatory and Clinical.

CATALYSTS IN FEED

168

AVG MAX MOVE

+116.8%

POSITIVE MOVES

100%

LARGEST MOVE

+664.1%

DSMB Efficacy Met FDA 510(k) Cleared FDA Approval FDA Fast Track FDA Meeting FDA Meeting Granted Generic Drug Approved Inconclusive Topline Results IND Cleared for Study IND Filed NDA Resubmission Orphan Drug Designation Positive Subgroup Data Positive Topline Results Primary Endpoint Met SPA Agreement Study Complete Trial Enrollment Complete

Range–Clear

Showing 7 of 20

Regulatory and ClinicalPositive Topline ResultsOct 5, 2026 · 5:23am ET

PCVXVaxcyte, Inc.

Vaxcyte Announced Positive Topline Data from OPUS-1 Phase 3 Trial of VAX-31

The pivotal adult Phase 3 trial results for the 31-valent pneumococcal conjugate vaccine candidate were positive.

Be first on the next Regulatory and Clinical catalyst.

Day Trader Sniper alerts you the instant a setup like this triggers.

Download Free →

Max move

+86.4%

RVOL

11.9x

Max high

$107.34

Fuel

52m

Regulatory and ClinicalPositive Topline ResultsOct 5, 2026 · 5:23am ET

PCVXVaxcyte, Inc.+86.4%

Vaxcyte Announced Positive Topline Data from OPUS-1 Phase 3 Trial of VAX-31

RVOL

11.9x

Max high

$107.34

Fuel

52m

Regulatory and ClinicalPositive Topline ResultsSep 30, 2026 · 7:03am ET

CNTBConnect Biopharma Holdings Ltd

Connect Biopharma Announces Positive Preliminary Topline Data from Global Phase 2 Study of Rademikibart

The study focused on Rademikibart as an add-on treatment for acute exacerbations in adults with COPD and Type 2 inflammation.

Regulatory and ClinicalPositive Topline ResultsSep 30, 2026 · 7:03am ET

CNTBConnect Biopharma Holdings Ltd+102.4%

Connect Biopharma Announces Positive Preliminary Topline Data from Global Phase 2 Study of Rademikibart

Regulatory and ClinicalPositive Topline ResultsSep 22, 2026 · 7:04am ET

VKTXViking Therapeutics, Inc.

Viking Therapeutics Announced Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735

The study demonstrated the promise of multiple maintenance dosing regimens.

Regulatory and ClinicalPositive Topline ResultsSep 22, 2026 · 7:04am ET

VKTXViking Therapeutics, Inc.+45.9%

Viking Therapeutics Announced Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735

Regulatory and ClinicalPositive Topline ResultsSep 22, 2026 · 7:01am ET

CLDXCelldex Therapeutics, Inc.

Celldex Therapeutics Announces Positive Phase 3 Results for Barzolvolimab

Studies met primary and all key secondary endpoints.

Regulatory and ClinicalPositive Topline ResultsSep 22, 2026 · 7:01am ET

CLDXCelldex Therapeutics, Inc.+39.5%

Celldex Therapeutics Announces Positive Phase 3 Results for Barzolvolimab

Regulatory and ClinicalPositive Topline ResultsAug 19, 2026 · 8:30am ET

BDRXBiodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc Announces Major Milestone for Serenta Phase 3 Trial

The company reached a significant achievement in its FAP treatment study.

Regulatory and ClinicalPositive Topline ResultsAug 19, 2026 · 8:30am ET

BDRXBiodexa Pharmaceuticals Plc+34.9%

Biodexa Pharmaceuticals Plc Announces Major Milestone for Serenta Phase 3 Trial

Regulatory and ClinicalPositive Topline ResultsAug 18, 2026 · 7:35am ET

AMLXAmylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Trial of Avexitide

The trial focused on post-bariatric hypoglycemia.

Regulatory and ClinicalPositive Topline ResultsAug 18, 2026 · 7:35am ET

AMLXAmylyx Pharmaceuticals, Inc.+48.6%

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Trial of Avexitide

Regulatory and ClinicalPositive Topline ResultsAug 17, 2026 · 4:00pm ET

AMLXAmylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Announces Topline Results from Phase 3 LUCIDITY Trial of Avexitide

Company to reveal outcomes for Avexitide in post-bariatric hypoglycemia patients.

Regulatory and ClinicalPositive Topline ResultsAug 17, 2026 · 4:00pm ET

AMLXAmylyx Pharmaceuticals, Inc.+65.1%

Amylyx Pharmaceuticals Announces Topline Results from Phase 3 LUCIDITY Trial of Avexitide

← Previous

1
2
3

RVOL

0.9x

Max high

$2.06

Fuel

1h 4m

RVOL

2.7x

Max high

$45.93

Fuel

27m

RVOL

1.1x

Max high

$53.65

Fuel

6m

RVOL

1.1x

Max high

$2.01

Fuel

1m

RVOL

11.4x

Max high

$36.33

Fuel

8h 40m

RVOL

1.0x

Max high

$35.39

Fuel

11h 57m